Alimta + Avastin = Failed Phase III First-line NSCLC Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
When added to a frontline NSCLC regimen with Roche’s Avastin, Lilly’s Alimta fails to improve survival in nonsquamous non-small cell lung cancer, but does modestly improve progression-free survival.